DNMT1 and ovarian cancer: Lastly, the utilisation of the CRISPR/Cas9 system in a folate receptor-targeted cationic liposome (F-LP) to target the DNA methyltransferase 1 (gDMNMT1) gene, whose overexpression results in inactivation or tumour suppressor genes and increased ovarian cancer cell resistance, resulted in the inhibition of ovarian cancer tumours both in vitro and in vivo [77].